TARBP2 Promotes Tumor Angiogenesis and Metastasis by Destabilizing Antiangiogenic Factor MRNAs

Overview

Journal Cancer Sci

Specialty Oncology

Date 2021 Jan 23

PMID 33484209

Citations 8

Authors

Meicen Zhou

Wenbao Lu

Bingwei Li

Xueting Liu

Ailing Li

Affiliations

Soon will be listed here.

Abstract

Tumor angiogenesis is a crucial step in the further growth and metastasis of solid tumors. However, its regulatory mechanism remains unclear. Here, we showed that TARBP2, an RNA-binding protein, played a role in promoting tumor-induced angiogenesis both in vitro and in vivo through degrading the mRNAs of antiangiogenic factors, including thrombospondin1/2 (THBS1/2), tissue inhibitor of metalloproteinases 1 (TIMP1), and serpin family F member 1 (SERPINF1), by targeting their 3'untranslated regions (3'UTRs). Overexpression of TARBP2 promotes tumor cell-induced angiogenesis, while its knockdown inhibits tumor angiogenesis. Clinical cohort analysis revealed that high expression level of TARBP2 was associated with poor survival of lung cancer and breast cancer patients. Mechanistically, TARBP2 physically interacts with the stem-loop structure located in the 3'UTR of antiangiogenic transcripts, leading to mRNA destabilization by the dsRNA-binding domains 1/2 (dsRBDs1/2). Notably, the expression level of TARBP2 in human tumor tissue is negatively correlated with the expression of antiangiogenic factors, including THBS1/2, and brain-specific angiogenesis inhibitor 1 (BAI1). Moreover, TARBP2 expression is strongly associated with tumor angiogenesis in a group of human lung cancer samples. Collectively, our results highlight that TARBP2 is a novel tumor angiogenesis regulator that could promote tumor angiogenesis by selectively downregulating antiangiogenic gene expression.

Citing Articles

Arid4a Suppresses Breast Tumor Metastasis by Enhancing MTSS1 Expression via mRNA Stability.

Wan P, Zhang D, Liu X, Lu W Cancer Med. 2025; 14(5):e70732.

PMID: 40066676 PMC: 11894439. DOI: 10.1002/cam4.70732.

Targeted intervention of tumor microenvironment with HDAC inhibitors and their combination therapy strategies.

Zhang W, Ge L, Zhang Y, Zhang Z, Zhang W, Song F Eur J Med Res. 2025; 30(1):69.

PMID: 39905506 PMC: 11792708. DOI: 10.1186/s40001-025-02326-8.

TRBP2, a Major Component of the RNAi Machinery, Is Subjected to Cell Cycle-Dependent Regulation in Human Cancer Cells of Diverse Tissue Origin.

Theotoki E, Kakoulidis P, Velentzas A, Nikolakopoulos K, Angelis N, Tsitsilonis O Cancers (Basel). 2024; 16(21).

PMID: 39518139 PMC: 11545598. DOI: 10.3390/cancers16213701.

RNA-binding proteins and exoribonucleases modulating miRNA in cancer: the enemy within.

Seo Y, Rhim J, Kim J Exp Mol Med. 2024; 56(5):1080-1106.

PMID: 38689093 PMC: 11148060. DOI: 10.1038/s12276-024-01224-z.

Functional Role of RBP in Osteosarcoma: Regulatory Mechanism and Clinical Therapy.

Que Z, Yang K, Wang N, Li S, Li T Anal Cell Pathol (Amst). 2023; 2023:9849719.

PMID: 37426488 PMC: 10328736. DOI: 10.1155/2023/9849719.

References

Goodarzi H, Zhang S, Buss C, Fish L, Tavazoie S, Tavazoie S . Metastasis-suppressor transcript destabilization through TARBP2 binding of mRNA hairpins. Nature. 2014; 513(7517):256-60. PMC: 4440807. DOI: 10.1038/nature13466. View

Lee H, Zhou K, Smith A, Noland C, Doudna J . Differential roles of human Dicer-binding proteins TRBP and PACT in small RNA processing. Nucleic Acids Res. 2013; 41(13):6568-76. PMC: 3711433. DOI: 10.1093/nar/gkt361. View

Kozak C, Gatignol A, Graham K, Jeang K, MCBRIDE O . Genetic mapping in human and mouse of the locus encoding TRBP, a protein that binds the TAR region of the human immunodeficiency virus (HIV-1). Genomics. 1995; 25(1):66-72. DOI: 10.1016/0888-7543(95)80110-8. View

Caramuta S, Lee L, Ozata D, Akcakaya P, Xie H, Hoog A . Clinical and functional impact of TARBP2 over-expression in adrenocortical carcinoma. Endocr Relat Cancer. 2013; 20(4):551-64. PMC: 3709642. DOI: 10.1530/ERC-13-0098. View

Sand M, Skrygan M, Georgas D, Sand D, Gambichler T, Altmeyer P . The miRNA machinery in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases and benign melanocytic nevi. Cell Tissue Res. 2012; 350(1):119-26. DOI: 10.1007/s00441-012-1446-0. View

Zerrouqi A, Pyrzynska B, Febbraio M, Brat D, Van Meir E . P14ARF inhibits human glioblastoma-induced angiogenesis by upregulating the expression of TIMP3. J Clin Invest. 2012; 122(4):1283-95. PMC: 3314443. DOI: 10.1172/JCI38596. View

Chen G, Gu H, Fang T, Zhou K, Xu J, Yin X . Hypoxia-induced let-7f-5p/TARBP2 feedback loop regulates osteosarcoma cell proliferation and invasion by inhibiting the Wnt signaling pathway. Aging (Albany NY). 2020; 12(8):6891-6903. PMC: 7202494. DOI: 10.18632/aging.103049. View

Bai S, Nunez A, Wei S, Ziober A, Yao Y, Tomaszewski J . Microsatellite instability and TARBP2 mutation study in upper urinary tract urothelial carcinoma. Am J Clin Pathol. 2013; 139(6):765-70. DOI: 10.1309/AJCPBSLP8XHSWLOW. View

Rhodes D, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D . ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia. 2004; 6(1):1-6. PMC: 1635162. DOI: 10.1016/s1476-5586(04)80047-2. View

10.

Zacchigna S, Zentilin L, Morini M, Delleva R, Noonan D, Albini A . AAV-mediated gene transfer of tissue inhibitor of metalloproteinases-1 inhibits vascular tumor growth and angiogenesis in vivo. Cancer Gene Ther. 2003; 11(1):73-80. DOI: 10.1038/sj.cgt.7700657. View

11.

Sand M, Skrygan M, Georgas D, Arenz C, Gambichler T, Sand D . Expression levels of the microRNA maturing microprocessor complex component DGCR8 and the RNA-induced silencing complex (RISC) components argonaute-1, argonaute-2, PACT, TARBP1, and TARBP2 in epithelial skin cancer. Mol Carcinog. 2011; 51(11):916-22. DOI: 10.1002/mc.20861. View

12.

De Vito C, Riggi N, Cornaz S, Suva M, Baumer K, Provero P . A TARBP2-dependent miRNA expression profile underlies cancer stem cell properties and provides candidate therapeutic reagents in Ewing sarcoma. Cancer Cell. 2012; 21(6):807-21. DOI: 10.1016/j.ccr.2012.04.023. View

13.

Shi Y, Zuo D, Wang X, Han M, Wu Y . shRNA‑mediated silencing of TARBP2 inhibits NCI‑H1299 non‑small cell lung cancer cell invasion and migration via the JNK/STAT3/AKT pathway. Mol Med Rep. 2016; 14(4):3725-30. DOI: 10.3892/mmr.2016.5723. View

14.

Fish L, Navickas A, Culbertson B, Xu Y, Nguyen H, Zhang S . Nuclear TARBP2 Drives Oncogenic Dysregulation of RNA Splicing and Decay. Mol Cell. 2019; 75(5):967-981.e9. PMC: 6731133. DOI: 10.1016/j.molcel.2019.06.001. View

15.

Kim D, Jang J, Ham S, Choi S, Park S, Jeong S . Doxorubicin inhibits PD-L1 expression by enhancing TTP-mediated decay of PD-L1 mRNA in cancer cells. Biochem Biophys Res Commun. 2019; 522(2):402-407. DOI: 10.1016/j.bbrc.2019.11.106. View

16.

Viallard C, Larrivee B . Tumor angiogenesis and vascular normalization: alternative therapeutic targets. Angiogenesis. 2017; 20(4):409-426. DOI: 10.1007/s10456-017-9562-9. View

17.

Weis S, Cheresh D . Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med. 2011; 17(11):1359-70. DOI: 10.1038/nm.2537. View

18.

Husemann Y, Geigl J, Schubert F, Musiani P, Meyer M, Burghart E . Systemic spread is an early step in breast cancer. Cancer Cell. 2008; 13(1):58-68. DOI: 10.1016/j.ccr.2007.12.003. View

19.

Fidler I . Critical determinants of metastasis. Semin Cancer Biol. 2002; 12(2):89-96. DOI: 10.1006/scbi.2001.0416. View

20.

Ling T, Li S, Weng G, Wang W, Li C, Cao L . TARBP2 negatively regulates IFN-β production and innate antiviral response by targeting MAVS. Mol Immunol. 2018; 104:1-10. DOI: 10.1016/j.molimm.2018.10.017. View